BCL2L1 and glioblastoma: Hypoxia has been reported to promote temozolomide (TMZ) resistance in glioblastoma multiforme (GBM), through the activation of HIF-1α and NF-κB, followed by upregulated expression of Bcl-xL (Kitange et al., 2009; Chen W.L. et al., 2015).